Briefing
Trastuzumab deruxtecan versus standard therapy for molecular relapse in early breast cancer
Phase 3 randomized trial of trastuzumab deruxtecan versus standard therapy after molecular relapse. The registry primary outcome is the ctDNA clearance rate 12 months after randomization. ClinicalTrials.gov lists the study as recruiting.
- Design: Phase 3 · Recruiting